Product Overview

Hzymes recombinant enterokinase (rEK) is expressed in E. coli and contains a His-tag. It has been mutated based on the native enterokinase light chain to achieve higher specific activity and cleavage specificity, making it especially suitable for production of peptide drugs such as GLP-1 and its analogs.

Key Features

High Cleavage Specificity

Engineered based on the native enterokinase light chain to provide specific recognition and cleavage of the DDDDK sequence, helping minimize non-specific proteolysis.

Efficient Tag Removal

Designed to support the efficient removal of fusion tags in recombinant protein and peptide production workflows.

GMP-Grade Manufacturing

Manufactured under a comprehensive GMP quality system, with established controls for traceability, consistency, and process documentation.

Recombinant E. coli Expression System

Produced using a recombinant E. coli expression platform and supplied with a His-tag to support quality control and manufacturing consistency.

Suitable for Peptide Production

Developed for applications requiring reliable enzymatic cleavage during the preparation of peptide intermediates and therapeutic peptides.

Applications

GLP-1 and Peptide Drug Manufacturing

Suitable for the production and preparation of peptide therapeutics, including GLP-1 and related peptide analogs.

Fusion Tag Removal

Applicable to the specific cleavage of DDDDK-tagged recombinant proteins and peptides during downstream processing.

Process Development and Scale-Up

Supports process development, pilot production, and commercial manufacturing workflows involving enterokinase-mediated cleavage.

GMP Manufacturing Workflows

Can be integrated into quality-controlled manufacturing processes where GMP-grade enzymes are required.

Performance Data